This is an important story from The Hill. Not because it’s insightful or even particularly good, but because I think it reflects a dangerous kind of conventional wisdom that is
The most-clicked link yesterday was to a study about the discount rates used in HTA calculations. You are all hopelessly geeky, and that warms my heart. Once upon a time,
This seems like a good time to remind the few folks who aren’t already tracking: Drug Channels’ Adam Fein is hosting his next webinar — on the impact of the
Reading Bob Herman’s new STAT piece about the newest PBM tactic -- something called “rebate credits” -- is kind of tough sledding. The source materials aren’t made available, so his
I know I said that Cost Curve would be off today, but there were three items that caught my eye yesterday that I wanted to make sure I shared before
Scheduling Note: Cost Curve is off tomorrow, back on Monday. Oh, we’re heavy into transparency report season now. I’ve dug up two additional sources for list- and net-price changes, which
It’s a big 340B day, starting with a decision by a federal appeals court to side with Arkansas in a dispute with PhRMA. Arkansas has a law that says that
Yesterday, I wrote about the State of the Union speech, noting that the Biden proposal to expand the number of medicines to face negotiations was weirdly meaningless (Biden wants 500
I’m back -- 100% back -- from last week, where I was super-sick on Wednesday, rallied for a 6 a.m. flight the next day, and closed on my new home
I woke up this morning not feeling myself. Per Binax, I’m technically fine, COVID-wise, but I was still thrown for a loop. I’d intended to take tomorrow off -- there’s